JAMA Cardiology RCT shows cardiorenal outcomes with tirzepatide vs. dulaglutide in diabetes/cardiovascular disease patients. Population: 9348 male, 3817 female. Intervention: 13299 randomized. Graph compares cumulative incidence of both.
In patients w/ type 2 #diabetes and #cardiovascular disease, the dual #GLP1/glucose-dependent insulinotropic polypeptide agonist #tirzepatide was associated w/ a lower incidence of major cardiorenal events compared with dulaglutide.
#ACC26 @accintouch.bsky.social
ja.ma/4s1pCfZ